FDA lifts clinical hold on Merck KGaA's Stimuvax cancer vaccine study
This article was originally published in Pharmaceutical Approvals Monthly
Merck KGaA and U.S. affiliate EMD Serono will resume two studies of experimental cancer immunotherapy Stimuvax (BLP liposome vaccine) in patients with non-small cell lung cancer after FDA partially lifted the clinical hold it placed on the entire Stimuvax program in March (1"The Pink Sheet" DAILY, March 23, 2010). A third study, STRIDE, in advanced breast cancer, remains on hold while Merck and the agency decide on next steps, Merck said June 17. The hold followed a case of encephalitis observed in a patient enrolled in an exploratory Phase II trial of the vaccine in patients with multiple myeloma. Protocol in the two NSCLC trials, START and INSPIRE, are being amended to add specific safety measures in response to the serious adverse event
You may also be interested in...
Merck KGaA Cancer Vaccine Studies On Clinical Hold Because Of Encephalitis, But AE Isn't In Lead Indications
The single event occurred in an exploratory study with a very different patient population and regimen than Phase III trials of the vaccine against lung and breast cancers, leaving hope the setback will be short-lived.
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.